To determine whether NEDD1 constitutes a potential target for future anti-cancer therapy, we investigate here the consequences of NEDD1-depletion by RNA silencing in a variety of cancer cell lines, and we analyse the effects of depletion on the cell cycle and on potential sensitisation to anti-mitotic agents. The gene discussed is NEDD1; the disease is cancer.